Vol 68, No 3 (2017)
Original paper
Published online: 2017-03-29

open access

Page views 1946
Article views/downloads 1779
Get Citation

Connect on Social Media

Connect on Social Media

Comparison of leukocyte IL6 expression in patients with gestational diabetes mellitus (GDM) diagnosed by the Polish Diabetes Association (PDA) 2011 and 2014 criteria

Katarzyna Mac-Marcjanek1, Andrzej Zieleniak1, Lucyna Woźniak1, Monika Źurawska-Kliś23, Katarzyna Cypryk23, Piotr Okła1, Marzena Wójcik1
Pubmed: 28353315
Endokrynol Pol 2017;68(3):317-325.


Introduction: Controversial data exist in the literature regarding relationship of IL-6 with gestational diabetes mellitus (GDM), partially resulting from different criteria for GDM classification. In the present study, we revised this linkage by investigating leukocyte IL6 expression and its associations with clinical characteristics of patients diagnosed by the Polish Diabetes Association (PDA) 2011 and 2014 criteria.

Material and methods: A total of 145 pregnant women underwent 75 g two-hour OGTT, and GDM was diagnosed according to PDA 2011 criteria (GDM/PDA 2011 group; n = 113) and PDA 2014 criteria (GDM/PDA 2014 group; n = 104). IL6 gene expression was investigated in leukocytes of all participants by using real-time PCR method.

Results: Compared to respective NGT control groups, the GDM/PDA 2011 group exhibited higher FPG, two-hour OGTT, HbA1C and IL6 expression and lower HDL-C, whereas the GDM/PDA 2014 group had higher FPG, one-hour and two-hour OGTT, HbA1C and HOMA-IR, lower QUICKI-IS, and unchanged IL6 expression. No differences in metabolic parameters and IL6 expression were found between the two GDM groups. Compared to the NGT/PDA 2011 group, the NGT/PDA 2014 group had lower one-hour and higher two-hour OGTT and increased IL6 expression. With PDA 2014 criteria, IL6 expression correlated positively with two-hour OGTT in both NGT and GDM groups as well as with LDL-C in NGT group, and negatively with HDL-C in NGT group. With PDA 2011 criteria, no associations were evident in NGT and GDM groups. Nevertheless, significant positive correlation of IL6 mRNA with two-hour OGTT was observed in the entire study group.

Conclusions: Differences in metabolic phenotypes as well as gene expression and correlation data between GDM and NGT groups, categorised based on PDA 2011 and 2014 criteria, are related to changes in gestational glucose tolerance status resulting from using PDA 2014 criteria. Moreover, our findings support the hypothesis that IL-6 is associated with glucose metabolism during pregnancy.


  1. Forsbach-Sánchez G, Tamez-Peréz HE, Vazquez-Lara J. Diabetes and pregnancy. Arch Med Res. 2005; 36(3): 291–299.
  2. Ożegowska-Wender E, Sporna M, Zawiejska A, et al. Wykładniki zespołu metabolicznego u kobiet po przebytej cukrzycy ciążowej. Pol Arch Med Wewn. 2007; 117: 457–461.
  3. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009; 373(9677): 1773–1779.
  4. Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008; 31(8): 1668–1669.
  5. Metzger BE. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. Clin Obstet Gynecol. 2007; 50(4): 972–979.
  6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7): 539–553.
  7. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Prakt. 2011; 12(Supl. A): A1–A46.
  8. Metzger BE, Lowe LP, Dyer AR, et al. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008; 358(19): 1991–2002.
  9. Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3): 676–682.
  10. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014; 103(3): 341–363.
  11. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2014. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetol Klin. 2014; 3(Supl. A): A1–A67.
  12. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005; 54 Suppl 2: S114–S124.
  13. Gomes CP, Torloni MR, Gueuvoghlanian-Silva BY, et al. Cytokine levels in gestational diabetes mellitus: a systematic review of the literature. Am J Reprod Immunol. 2013; 69(6): 545–557.
  14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  15. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85(7): 2402–2410.
  16. Wójcik M, Mac-Marcjanek K, Woźniak LA, et al. The association of leukocyte phosphatidylinositol 3-kinase delta overexpression with gestational diabetes mellitus (GDM). Endokrynol Pol. 2014; 65(1): 17–24.
  17. Wojcik M, Zieleniak A, Mac-Marcjanek K, et al. The elevated gene expression level of the A(2B) adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus. Diabetes Metab Res Rev. 2014; 30(1): 42–53.
  18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
  19. Endo S, Maeda K, Suto M, et al. Differences in insulin sensitivity in pregnant women with overweight and gestational diabetes mellitus. Gynecol Endocrinol. 2006; 22(6): 343–349.
  20. Wolf M, Sandler L, Hsu K, et al. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care. 2003; 26(3): 819–824.
  21. Leipold H, Worda C, Gruber CJ, et al. Gestational diabetes mellitus is associated with increased C-reactive protein concentrations in the third but not second trimester. Eur J Clin Invest. 2005; 35(12): 752–757.
  22. Retnakaran R, Hanley AJG, Raif N, et al. C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab. 2003; 88(8): 3507–3512.
  23. Evangelista AF, Collares CVA, Xavier DJ, et al. Integrative analysis of the transcriptome profiles observed in type 1, type 2 and gestational diabetes mellitus reveals the role of inflammation. BMC Med Genomics. 2014; 7: 28.
  24. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999; 36(1-2): 67–72.
  25. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12): 4196–4200.
  26. Spoto B, Di Betta E, Mattace-Raso F, et al. Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity. Nutr Metab Cardiovasc Dis. 2014; 24(10): 1137–1143.
  27. Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002; 45(6): 805–812.
  28. Kuzmicki M, Telejko B, Szamatowicz J, et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol. 2009; 25(4): 258–263.
  29. Kuzmicki M, Telejko B, Zonenberg A, et al. Circulating pro- and anti-inflammatory cytokines in Polish women with gestational diabetes. Horm Metab Res. 2008; 40(8): 556–560.
  30. Georgiou HM, Lappas M, Georgiou GM, et al. Screening for biomarkers predictive of gestational diabetes mellitus. Acta Diabetol. 2008; 45(3): 157–165.
  31. Lappas M, Permezel M, Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta, adipose tissue, and skeletal muscle from normal pregnant women and women with gestational diabetes mellitus. J Clin Endocrinol Metab. 2004; 89(11): 5627–5633.
  32. Kleiblova P, Dostalova I, Bartlova M, et al. Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Mol Cell Endocrinol. 2010; 314(1): 150–156.
  33. Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 1997; 82(12): 4167–4170.
  34. Ritchie DG. Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol. 1990; 258(1 Pt 1): E57–E64.
  35. Devaraj S, Venugopal SK, Singh U, et al. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes. 2005; 54(1): 85–91.
  36. Morohoshi M, Fujisawa K, Uchimura I, et al. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci. 1995; 748: 562–570.
  37. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12:1179-1186.
  38. Zhang D, Sun M, Samols D, et al. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996; 271(16): 9503–9509.
  39. Agrawal A, Cha-Molstad H, Samols D, et al. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein beta (C/EBP beta) and Rel p50. J Immunol. 2001; 166(4): 2378–2384.
  40. Ganter U, Arcone R, Toniatti C, et al. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 1989; 8(12): 3773–3779.
  41. Gabay C, Porter B, Guenette D, et al. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood. 1999; 93(4): 1299–1307.
  42. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996; 87(9): 3615–3624.
  43. Yap SH, Moshage HJ, Hazenberg BP, et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1991; 1091(3): 405–408.
  44. Taylor AW, Ku NO, Mortensen RF. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J Immunol. 1990; 145(8): 2507–2513.